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Introduction
Retinoblastoma (RB) is a childhood eye cancer that constitutes 
around 3% of all childhood malignancies globally. RB leads 
to complete vision loss if untreated and causes mortality at 
advanced stages if not enucleated.1 Therefore, better treatment 
modalities are needed for eye salvage and good life by develop-
ing targeted therapies specific for RB cells. The retina majorly 
consists of glycerophospholipids which are further classified 
into phosphatidylethanolamines (PEs) and phosphatidylcho-
lines (PCs).2,3 Recently, lipid imaging using desorption electro-
spray ionization mass spectrometry (DESI MS) has emerged 
as a powerful methodology to precisely measure metabolites in 
tissues and to study lipid changes between normal versus can-
cerous tissue.4 DESI MS-based lipid imaging would potentially 
assist to study the biology of retinal diseases.
Nucleolin (NCL) is a multifunctional protein that actively par-
ticipates in the rDNA transcription, translocation of rRNA,5,6 
growth, and proliferation of cells. It interacts with G-quadru-
plex structures in the promoter regions of c-Myc, untranslated 
regions (5’ UTRs) of various mRNAs,7–9 and microproces-
sor machinery for the microRNA biogenesis10,11 NCL protein 
expression on the cell surface has been identified in many epi-
thelial cancers.8,12,13 The presence of surface NCL in cancer 
cells in contrast to the non-neoplastic cells makes it a promis-
ing target for the cancer therapy.8,14,15 Aptamers are oligonu-
cleotides developed using Systemic Evolution of Ligands by 
EXponential enrichment (SELEX) method. These molecules 
possess high affinity towards the target molecules owing to its 
specific three dimensional structures. Aptamers16 are utilized 
as diagnostic and therapeutic tools in oncology. An aptamer 
against NCL, NCL-APT also known as AS1411 (Antisoma, 
UK), is a US Food and Drug Administration (FDA)-approved 
NCL targeting agent. It binds to NCL on the cell surface, pref-
erentially gets internalized, and inhibits cancer cell growth 
sparing normal cells17–19 and hence we utilized this aptamer to 
study its effect against RB.
DESI MS can potentially grade the stages in cancer, 
detect the surgical tumor margins, and study lipogenesis in 
tumor.4,20–22 DESI MS-based lipid imaging of cultured RB cells 
was recently optimized by spotting cells onto Whatman filter 
paper23 and this method was utilized for studying the aptamer 
siRNA chimera-mediated changes in cell lines.24 There is 
no information on the expression status of NCL in RB and 
on the use of lipid imaging to study the effect of NCL-APT 
in situ. In this report, we studied the role of NCL in RB and 
targeted it using a NCL-APT and LNA modified NCL-APT 
(LNA-NCL-APT). We also studied the NCL-APT influence on 
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Retinoblastoma (RB) is an intraocular childhood tumor which, if left untreated, leads to blindness and mortality. Nucleolin 
(NCL) protein which is differentially expressed on the tumor cell surface, binds ligands and regulates carcinogenesis and 
angiogenesis. We found that NCL is over expressed in RB tumor tissues and cell lines compared to normal retina. We studied 
the effect of nucleolin-aptamer (NCL-APT) to reduce proliferation in RB tumor cells. Aptamer treatment on the RB cell lines 
(Y79 and WERI-Rb1) led to significant inhibition of cell proliferation. Locked nucleic acid (LNA) modified NCL-APT administered 
subcutaneously (s.c.) near tumor or intraperitoneally (i.p.) in Y79 xenografted nude mice resulted in 26 and 65% of tumor growth 
inhibition, respectively. Downregulation of inhibitor of apoptosis proteins, tumor miRNA-18a, altered serum cytokines, and 
serum miRNA-18a levels were observed upon NCL-APT treatment. Desorption electrospray ionization mass spectrometry (DESI 
MS)-based imaging of cell lines and tumor tissues revealed changes in phosphatidylcholines levels upon treatment. Thus, 
our study provides proof of concept illustrating NCL-APT-based targeted therapeutic strategy and use of DESI MS-based lipid 
imaging in monitoring therapeutic responses in RB.
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relevant genes, microRNAs, and lipids expressed on the RB 
cells using in vitro and in vivo models. We showed that DESI 
MS based lipid imaging can help in understanding NCL-APT 
treatment induced changes in RB.
Results
NCL expression in RB and uptake of NCL-APT
The lack of information on the status of NCL in RB intrigued 
us to investigate the expression of NCL on RB tumor sam-
ples and it was analyzed by qPCR, immunohistochemistry 
(IHC), flow cytometry, and immunoblotting. The change in 
NCL mRNA expression across the RB tumors normalized 
to normal retina varied between 0.45-and 6.56-fold with 
mean expression levels of 3.94 ± 1.87-fold. The samples with 
NCL mRNA upregulated more than twofold (marked by the 
threshold line) were considered as significant. The RB cell 
lines showed NCL mRNA upregulation of 4.8-fold in Y79 and 
3.0-fold in WERI-Rb1 cells upon normalizing with MIO-M1, a 
nonmalignant control cell line (Figure 1a). IHC studies of NCL 
protein expression in 25 cases of RB primary tumor sections 
showed membrane/cytoplasmic positivity in the RB cells. The 
healthy cadaveric retinal tissues (n = 2) showed faint nuclear 
staining and no cytoplasmic staining (Figure 1b, i, ii). The 
staining pattern within the tumor was heterogeneous and 
on an average, 50% of cells showed positive, and in a few 
cases, more than 70% of cells were positive for NCL protein 
 (Figure 1b, iii, iv).
Cytoplasmic NCL protein expression levels studied by 
immunoblotting in both the non-neoplastic retina and RB 
samples showed overexpression of NCL in the RB tissues. 
Densitometry analysis of the blots showed significant upregu-
lation of NCL in cytoplasm of the RB tumor cells (Figure 1c). 
Ten RB tumors were analyzed by flow cytometry which were 
found to be highly positive (>60% of cells) for NCL and the 
respective scatter plot is shown in Figure 1d. The overlay plot 
shows the expression of NCL in Y79 and WERI-Rb1 cells as 
analyzed by flow cytometry (Supplementary Figure S1A). 
AS1411 or NCL-APT has been shown to preferentially inter-
nalize into the cancer cells by utilizing the cell surface NCL. 
Elevated levels of NCL in the cytoplasm and cell surface of 
the RB tumor cells could thus aid in NCL-APT uptake and 
functional activity in RB tumor cells respectively. Preferen-
tial uptake of FITC labelled NCL-APT was observed in Y79 
and WERI-Rb1 cells than MIO-M1 cell line  (Supplementary 
 Figure S1B). Also, the cell cycle changes analyzed post-
NCL-APT treatment in cell lines showed increase in G0-G1 
phase in WERI-Rb1 and arrest in S phase in Y79. MIO-M1 
cells did not exert considerable changes in different cell 
phases (Supplementary Figure S1C). Thus, we were able 
to observe the differential expression of NCL in the RB cells 
and cell lines and NCL-APT internalization mediated cell 
cycle changes.
NCL-APT regulates oncogenic miRNAs in RB
NCL is shown to involve in microprocessor machinery and 
regulates the DICER expression.10
 As the dicer participa-
tion in microprocessor is essential for miRNA expression, we 
investigated the influence of the NCL-APT on miRNA expres-
sion in RB. miR-15a, miR-16, and miR-221 family were earlier 
reported for their altered expression upon NCL-APT treatment 
Figure 1 Expression of nucleolin in RB tumor samples and cell lines. (a) Fold changes in gene expression of NCL in various primary cells 
and cell lines. (b) Immunohistochemistry of the normal retina section (i, ii), RB tissue sections (iii, iv). (c) Expression of NCL in the cytoplasmic 
fraction of RB tumor tissues by immunoblotting for NCL and β-actin, graph on the right shows the densitometry analysis of tumor samples 
normalized to normal retina (NR). (d) Scatter plots show the expression of NCL and the NCL-APT binding to RB tumor (RB cells from the 
enucleated eyes). The error bar represents the SD and the * indicates significance of P < 0.05 and ** indicates significance of P < 0.001 when 
compared to the normal retina.
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in breast cancer. Thus, we studied the miRNA profiles in RB 
cell line after 48 hours of treatment with NCL-APT.14,15 NCL-
APT-treated WERI-Rb1 cells were subjected to miRNA 
microarray and the global miRNA expression profiling was 
performed. Hierarchical clustering of the miRNA showed sig-
nificant (P < 0.05) downregulation of 46 miRNAs (Figure 2a).
From the differentially regulated 46 miRNAs, four miR-
NAs (miR-196b, miR-152, miR-1, and miR-330) and mature 
miRNAs of oncomir-1 cluster (miR-17–92 cluster) previously 
reported in RB25 were studied using qPCR for their native 
expression in RB cell lines by normalizing to MIO-M1 cells. 
The fold change in expression of the mature miRNAs of miR-
17–92 cluster was similar except for miR-17 and miR-18a 
in both the RB cell lines, while other three miRNAs except 
miR-330 were highly expressed in Y79 than WERI-Rb1 
(Supplementary Figure S2A). These miRNAs upon NCL-
APT treatment in both the RB cell lines were found down-
regulated, with marked effect in WERI-Rb1 cells confirmed 
by qPCR (Figure 2b). Thus, the miRNA-17–92 cluster and 
the other miRNAs downregulated in the miRNA profiling were 
validated for their changes in expression in both the RB cell 
lines.
NCL-APT perturbs RB in vitro and in vivo: effect on 
miRNAs, apoptotic proteins
We next investigated the functional activity of the NCL-APT on 
the RB cell growth and proliferation. The phenotypic changes 
monitored post NCL-APT treatment confirmed the cell cycle 
blockage at S phase (Supplementary Figure S2B). The 
antiproliferative property of the NCL-APT was tested using 
dimethyl thiazolyldiphenyl tetrazolium bromide (MTT) assay 
in RB cell lines and MIO-M1 cell line. Various concentra-
tions of NCL-APT (1, 5, 10, and 20 µmol/l) were studied in 
Y79, WERI-Rb1 and MIO-M1 cell lines and cell viabilities of 
40 ± 5.0, 42 ± 1.2, and 90 ± 1.9%, respectively were obtained 
at 20 µmol/l by MTT assay after 48 hours of treatment. A 
concentration of 10 µmol/l was used to study the molecular 
effects of NCL-APT as the viability was 74 and 63% in Y79 
and WERI-Rb1 cell lines, respectively with uncompromised 
viability in MIO-M1 cell line  (Figure 3a). Thus the inhibition of 
cell division lead to cytotoxicity leading to decrease in viabil-
ity of RB cell lines sparing the control retinal MIO-M1 cell line.
As LNA modification of nucleic acids imparts increased 
serum half life, we studied the stability of LNA modified NCL-
APT and found to be more stable than NCL-APT up to 120 
Figure 2 Effect of NCL-APT on miRNA expression. (a) Hierarchical clustering of the miRNAs from the WERI-Rb1 cell line and cells treated 
with NCL-APT. The colour range indicates the status of expression (yellow being midrange and green being downregulation). (b) Fold changes 
in the miRNA levels - mir-196b, mir-330, mir-152, mir-1, mir-17, mir-18a, mir-19-1, and mir-20a in Y79 and WERI-Rb1 cell lines treated with 
NCL-APT normalized with untreated cells.
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hours under physiological pH and in serum (Supplementary 
Figure S3). This LNA-NCL-APT having LNA bases at three 
positions exhibited higher in vivo stability with unaltered cyto-
static effect and was therefore included in the study.26 The 
antiproliferative effect of LNA-NCL-APT was assessed in 
Y79, WERI-Rb1, and MIO-M1 cell lines and found to have 
45 ± 6.8, 35 ± 9.0, and 84 ± 5.8% of cell viability after 48 
hours of treatment at the dose of 10 µmol/l. The activities 
were very similar not significantly different from the NCL-APT 
(Figure 3b). The scrambled aptamer carrying C’s instead of 
G’s in NCL-APT was tested against the RB and MIO-M1 cell 
lines. The scrambled aptamer did not affect significantly the 
cell viability of RB and MIO-M1 cell lines even at 20 µmol/l, 
thus confirming specificity of NCL-APT activity (Figure 3c).
The effect of NCL-APT and LNA-NCL-APT was studied 
in vivo in the RB tumor using Y79 xenograft in nude mice. 
The Y79 xenograft model has been shown for the aggressive 
tumor growth characteristics and hence we used Y79 xeno-
graft model than the WERI-Rb1-based xenograft model.27 The 
Y79 xenografted mice treated with NCL-APT and LNA-NCL-
APT subcutaneously (s.c.) near the tumor sites showed tumor 
growth reduction with the difference in mean tumor volume of 
380 and 440 mm3 respectively from the vehicle control group 
which was 1,289 mm3 (Figure 4a). The percentage tumor 
growth reduction/inhibition calculated were 22.2 and 26% in 
NCL-APT and LNA-NCL-APT treated s.c. at day 21 (Figure 
4b). Notably, the effect of LNA-NCL-APT by intraperitoneal 
(i.p.) injection showed better tumor growth reduction of about 
65% with difference in mean tumor volume of 450 mm3 at day 
15. The excised tumors from respective treatments showed 
clear size differences between the tumors (Figure 4c).
The NCL-APT and LNA-NCL-APT showed significant anti-
tumor activity in Y79 xenograft model at day 18 and day 21. 
The molecular mechanism behind the tumor growth reduc-
tion was addressed by analyzing the tumor mRNA, miRNA 
and apoptotic protein expression in representative samples 
of untreated, NCL-APT and LNA-NCL-APT (s.c.) and LNA-
NCL-APT (i.p.) treated xenograft tissues. Additionally, serum 
onco-miRNAs and cytokine levels were studied for correlat-
ing the tumor growth changes. Tumor miRNA expression 
was studied for the miR-17–92 cluster25,28,29 and miR-330, 
miR-206, miR-196b, and miR-152 that were differentially 
regulated by NCL-APT treatment in RB cell lines. The miR-
196b was downregulated in all the treated samples followed 
by the miR-330, miR-206, miR-196b, and miR-18a in most of 
the treated samples (Figure 5a). As observed in the miRNA 
microarray of cells treated with NCL-APT, the above miRNAs 
were downregulated in the xenografted tumor tissues. This 
signifies the influence of NCL-APT on the miRNA changes 
resulting in the changes of tumor growth.
Serum miRNA acts as bio-marker for diagnosis and prog-
nosis of diseases.30,31 Data from the RB patients showed that 
miR-17–92 cluster was overexpressed in serum, and hence 
changes in this serum miR-17–92 levels were of our interest.32 
The relative changes in serum miRNA between normal nude 
mice and Y79 xenografted mice serum showed elevated lev-
els of miR-18a and miR-19b-1 expression, followed by miR-17. 
The miR-17 and miR-19b-1 were downregulated in NCL-APT 
s.c. and LNA-NCL-APT i.p. groups, while miR-18a expression 
was affected at similar levels in all the treatment groups (Fig-
ure 5b). The immunoblot analysis of the apoptotic proteins, 
Bcl2 and survivin showed that their expressions were down-
regulated in all treated tissues with varying FOXM1 expression 
in different modes of treatments as observed by densitometry 
(Figure 5c). Thus the NCL-APT treatment in vitro and in vivo 
lead to RB growth inhibition mediated by the integrated regula-
tion of mRNAs, oncogenic miRNAs and apoptotic markers.
LNA-NCL-APT-mediated changes in apoptotic marker 
and cytokine levels: an integrome analysis
The integrated changes in proteome, miRNA and gene 
expression upon aptamer treatment and its analysis would be 
able to elucidate the molecular mechanism in RB. Hence we 
studied the changes in the tumor-apoptotic proteins and cyto-
kines in the xenograft treated with LNA-NCL-APT. The apop-
tosis markers studied by protein array from the tumor tissues 
treated with PBS and LNA-NCL-APT showed a significant dif-
ference in the extrinsic and intrinsic pathway mediators. There 
was significant decrease in XIAP, survivin, livin, cytochrome 
c, HSP27, clusterin and p21 with increase in the levels of 
Bad, Bcl-xl, Fas, TNFαR, and p53 (Figure 5d).  Additionally, 
the cytokines expression was studied for the involvement of 
Figure 3 Effect of NCL-APT on cell proliferation. NCL-APT and LNA-NCL-APT were assessed at the concentration of 1, 5, 10, and 20 
µmol/l on the cell lines after 48 hours of treatment. Graph showing the percentage cell viability exhibited by the NCL-APT (a) and LNA-NCL-
APT (b) on Y79, WERI-Rb1 and MIO-M1 cells at 48 hours using MTT assay. The Scrambled aptamer is treated at the concentration of 5 and 
20 µmol/l. (c). Graph showing the cell viabilities upon scrambled aptamer treatment assessed by MTT assay. The mean of triplicate data ± SD 
are plotted and the * indicates significance of P < 0.05, ** indicates significance of P < 0.001 and NS indicates not significant.
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immune mechanisms in tumor regression. Compared to the 
vehicle control, the LNA-NCL-APT treated groups showed 
significant (*P < 0.05) increase in the expression of CXCL1, 
CXCL12, TIMP1, MCSF, and i-309 with decreased levels of 
IL2, ITAC, and CCL2. Also, there was no significant difference 
in expression of TNF-α and IFN-γ. Thus, there were mixed 
expression of the chemotactic cytokines and the mitogenic 
cytokines upon the LNA-NCL-APT treatment (Figure 5e). IHC 
studies of LNA-NCL-APT i.p. treated tissues also exhibited 
decreased levels of the nuclear PCNA expression (Figure 5f).
Integrated network modelling and analysis of statistically 
significant enriched miRNA, genes and pathways revealed 
key pathways were altered during NCL-APT treatment. The 
affected pathways were apoptosis, cancer, cell cycle, immune 
response, and homeostasis, harboring genes like TP53, 
HSPD1, Bcl2, CXCL12, AKT1, MDM2, p21, CCL2, BIRC5, 
and IL2. Further, the integrome network of the above affected 
miRNAs, mRNAs and proteins showed miR-1, miR-17, and 
miR-206 to be key regulators of transcriptional response and 
by affecting apoptotic response by NCL-APT treatment (Sup-
plementary Figure S4).
Lipid profiling of xenograft tissues
The lipid content of the cell is important in the cellular 
metabolism and to maintain the normal behaviour of cells. 
Phosphatidylcholines are the major lipid present in the cell 
membrane and altered PCs and choline metabolites levels 
leads to changes in gene expression and cell proliferation 
as in the case of malignancy.33 In the current work, we stud-
ied the indirect effect of NCL in PCs levels using aptamer 
and siRNA strategy. The mass spectra were obtained for the 
Y79, WERI-Rb1, and MIO-M1 cell lines (Figure 6a) and the 
peaks observed in DESI MS were identified as PCs by MS/
MS and database search. The lipids corresponding to the 
different PCs are listed in Supplementary Table S1. The 
high intensity peaks observed in different RB cell lines were 
m/z 754.6 [PC(32:1)+Na]+, 782.6 [PC(34:1)+Na]+, 810.6 
[PC(36:1)+Na]+, and 832.7 [PC(38:4)+Na]+  (Figure 6a). 
The changes in expression of lipids [PC(32:1)+Na]+ and 
[PC(36:1)+Na]+ differ significantly from the untreated to 
NCL-APT and LNA-NCL-APT treated cells of Y79 and 
WERI-Rb1 (m/z 782.6 and 810.6) (Figure 6b,c). Two other 
significant lipid peaks, m/z 754.6 [PC(34:1)+Na]+ and 832.7 
[PC(38:4)+Na]+ were also studied in NCL-APT-treated RB 
cell lines (Supplementary Figure S5B). The effect of NCL 
on lipid levels was counter verified using silencing strategy. 
The siRNA against NCL was transfected, studied for NCL 
downregulation and its effect in lipid levels. Upon NCL down-
regulation in RB cell lines, the intensities of lipid peaks above 
studied were reduced (Supplementary Figure S5C). Thus, 
the use of NCL-APT or silencing NCL has similar effect on 
the predominantly identified lipids in RB cell lines studied by 
DESI MS.
To access if there is global alteration of lipid by NCL-
APT, we further evaluated the effect of both the NCL-APTs 
in prostate cancer cell line (PC3). The mass spectrum 
obtained from PC3 was presented with Y79 tumor xeno-
graft and Y79 cells (Supplementary Figure S6A). The high 
intensity peaks (m/z 754.6 and 782.6) observed in PC3 cell 
line were affected upon APT treatment, while MIO-M1 (m/z 
782.6 and 832.7) showed less intense changes by LNA-
NCL-APT and not by the NCL-APT treatment (Supplemen-
tary Figure S6B, C).
The Y79 xenografts treated with NCL-APT and LNA-
NCL-APT by s.c. route and i.p. route were subjected to lipid 
profiling. Analysis of tumor sections showed a decrease in 
intensities of lipids of m/z 782.6 and 810.6 in the NCL-APT 
s.c. and LNA-NCL-APT i.p. treated tissues followed by LNA-
NCL-APT s.c. treated tissue with insignificant changes in 
few areas of the tissues (Figure 7). In addition to the peaks 
studied above, two other lipid peaks m/z 754.6 and 832.7 
studied in APT-treated xenograft tissues were found to 
have similar changes (Supplementary Figure S6D). Over-
all majority of treated tissues were identified with lesser 
intensities of lipids with the i.p. mode of treatment showing 
lowest levels of lipids. The drastic changes in lipid levels 
proportionately correlates with the aptamer treatment, as 
the inhibition of lipid synthesis or decrease in lipids levels 
directly affects cell proliferation. Thus, we found that block-
ing of NCL function using NCL-APT has affected the lipid 
levels in the cells, thereby regulating the cell growth.
Figure 4 Antitumor effect of NCL-APT and LNA-NCL-APT on 
Y79 xenograft model. (a) Graph showing the change in percentage 
tumor growth inhibition of the groups injected with NCL-APT and 
LNA-NCL-APT subcutaneously near the tumor site and LNA-
NCL-APT by intraperitoneal route. Photographs showing the 
representative animals (b) and excised tumors (c) showing the 
changes in tumor growth upon treatment by s.c. and i.p. routes. 
The error bar in panel A represents the SEM and the * indicates 
significance of P < 0.05 and ** indicates significance of P <  0.001.
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Discussion
Our study showed the differential expression of NCL protein 
on the surface and cytoplasm of RB tumor cells. Targeting 
NCL using NCL-APT in the RB cell lines lead to downregu-
lation of oncogenic miRNAs and lead to inhibition cell pro-
liferation. NCL-APT and LNA modified NCL-APT-mediated 
inhibition of NCL, reduced phosphatidylcholine levels as con-
firmed by DESI MS of aptamer treated RB cells. Functional 
blocking of NCL from transcription and translation processes 
concomitantly resulted in the altered gene expression and 
lipid (PCs) levels. Similarly, the internalized NCL-APT leads 
to the cell cycle blockage due to the S phase arrest fol-
lowed by increase in the G0-G1 population. These changes 
in cell cycle and cell proliferation inhibition are in agree-
ment with the observations reported regarding the G-rich 
oligonucleotides.34,35
The maintenance of stability of oncogenic mRNAs and miR-
NAs is one of the essential steps in tumorigenesis. NCL plays 
a pivotal role in mRNA stabilization and enhanced translation 
in cancer.7,8 Global miRNA profiling of NCL-APT-treated RB 
cell line in the current study showed majorly downregulation 
of miRNAs with a few upregulated miRNAs confirming the 
importance of the NCL in the miRNA biogenesis.11 We further 
studied the expression of oncogenic miRNA pertaining to 
RB, miR-17–92 cluster and found downregulation upon treat-
ment. The differentially expressed miRNA studied includes 
miR-196b, miR-373, miR-330, miR-152 and miR-1. The 
observation of miRNA downregulation upon NCL-APT treat-
ment may be related to the regulation at transcription level 
leading to halt in the miRNA synthesis and processing. The 
NCL binding to the promoter G-quadruplex structure controls 
the transcription of c-myc gene.36 The promoter regions of 
these miRNA were predicted for the presence of G-quadru-
plex and i-tetraplex structures that could have mediated the 
effect.37
The tumor suppressor property of miR-152 and miR-1 in 
ovarian cancers38 and bladder cancer39 were reported earlier 
and in the current study these miRNAs were downregulated 
upon NCL-APT treatment, which could be attributed due to 
the promoter structure. NCL involvement in miRNA promot-
ers, however, needs further investigation. The miR-330 is 
Figure 5 Molecular changes accompanying NCL-APT and LNA-NCL-APT treatment on Y79 xenograft. (a) Graph showing the levels of 
Y79 xenograft tumor tissue miRNA (miR-330, miR-206, miR-196b and miR-18a) normalized to vehicle control using U6 as internal control. (b) 
Graph showing the levels of serum miRNA post treatment with nucleolin aptamer. Normal serum (mice without tumor) was used for normalizing 
the expression levels.(c) Western blotting for Bcl2, Survivin, FOXM1 proteins from xenograft tissues of the control group and treated group 
tissues. The levels of apoptotic markers (d) in tumor tissue and serum cytokines (e) using protein array. The integrated pixel densities of the 
spots were quantified using ImageJ software and plotted as graph. The error bar represents the SD and the * indicates significance of P<0.05 
and ** indicates significance of P < 0.001, for panel A, treated groups were normalized to vehicle control group, for panel B  - normal serum 
was compared to vehicle control, then the vehicle control group was used to analyze the significance in treated groups. (f) IHC for PCNA 
expression. The images are taken under 40X objective. The intensity of expression is indicated in the bottom left.
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reported as tumor suppressor miRNA in prostate cancer, but 
a recent report suggested inverse role in glioblastoma.40 The 
oncogenic role of miR-196b has been studied in glioblastoma 
and its expression correlated to poor disease prognosis41 
and this miRNA was upregulated in RB tumors too. Thus, the 
mature miRNAs of established onco-miRNA-1 cluster, miR-
17, miR-18a and miR-19b and miR-196b, miR-330, miR-152, 
miR-206, and miR-1 were found to be downregulated in the 
RB cell lines upon aptamer treatment.
The in vivo studies for evaluating the anti-tumor activity 
of NCL-APT and LNA-NCL-APT in Y79 xenograft revealed 
better effect in the i.p. mode of delivery than the s.c. mode 
of delivery. The NCL-APT and LNA-NCL-APT both showed 
tumor growth inhibition with later aptamer having 4% bet-
ter efficacy in tumor inhibition under s.c. mode, while the 
i.p. mode of LNA-NCL-APT delivery showed 65% of tumor 
growth inhibition. The absence of the i.p. mode of delivery for 
NCL-APT in the current study alleviates our ability to appre-
ciate LNA-NCL-APT over NCL-APT. This difference in the 
tumor reduction suggests that the delivery mode is important 
to attain better therapeutic efficacy. Intraperitoneal mode has 
been recognized for the better absorption and availability of 
substance injected.42 Also NCL-APT was delivered earlier 
studies by both i.p. or s.c. modes in mouse and in patients 
by continuous infusion method.11,43 Thus, the bioavailability of 
the LNA-NCL-APT to the tumor could have attributed to the 
results observed which desires further investigation.
The mechanism behind the antitumor activity of the LNA-
NCL-APT was studied by analyzing the tumor miRNAs and 
serum biomarkers in the i.p. mode of treatment as the effi-
cacy is better than the s.c. mode. The miRNA expression 
in the treated tumor revealed that there is consistent down-
regulation of miR-18a and miR-196b in the treated tumors. 
The decreased expression of the miR-18a and miR-196b 
could have enhanced the antitumor activity of aptamer in 
RB.25 The aptamer treatment had downregulated the levels 
of Bcl2,  survivin, and FOXM1 differentially. FOXM1 is over-
expressed in cancers, controlled through miRNA expres-
sion and cell cycle changes.44 Perturbation in cell division by 
stathmin silencing in RB cell lines showed FOXM1 upregu-
lation.45 FOXM1 upregulation has shown to induce genomic 
instability, leading to induction of p21, p53, and apoptosis 
of cells.46 Thus, our observation of differential regulation of 
FOXM1 needs further analysis. The protein array supports 
the apoptotic onset by the decrease of IAPs, increase in Bad 
and p53. The cytokine levels were also varying with some of 
the chemotactic attractants getting downregulated with minor 
or no changes in the levels of the TNF-α and IFN-γ. Thus, 
the multifunctional NCL protein expressed under cancerous 
condition modulates various activities.
Figure 6 DESI MS imaging of aptamer treated RB cell lines. (a) DESI-MS spectra of Y79, WERI-Rb1 and MIO-M1 cells grown in cell. 
Cells were washed with 1XPBS twice and spotted on Whatmann membrane and imaged using methanol as solvent using positive mode and 
data acquired from 50 to 2,000 Daltons. Changes in the lipid expression accompanying the treatment with nucleolin aptamer in RB cell line, 
Y79 (b) WERI-Rb1 (c).
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DESI MS is extensively used for lipidome analysis thereby 
discriminating stages of cancer, surgical margins of cancer-
ous to noncancerous regions and tumor heterogeneity.47,48 
We utilized DESI MS for observing the changes in the inten-
sity of PCs levels upon NCL-APT treatment in RB cell lines 
and tumor tissues. To check if NCL modulates the PCs lev-
els in other cancers, the effect of NCL-APT was tested using 
prostate cancer model, PC3 cell line. We confirmed that 
inhibiting NCL using NCL-APT effectively brought down the 
PC levels in PC3 cell lines too. Thus, we intended to check 
this mechanism in the in vivo model and the observed results 
in in vivo confirm the role of the NCL in the lipid metabolism 
using DESI MS. This approach of using DESI MS-based lipid 
imaging could also monitor the therapeutic progress.
Thus, we hypothesize that perturbing NCL function using 
NCL-APT impaired lipid synthesis and thereby altered PC 
levels on the cell membrane. This could indirectly explain the 
mechanism behind the tumor growth inhibition in the in vivo 
conditions. Similar observations using conditional knock on 
and knock off mice for the MYCN-oncogene were obtained 
in the lipid profiling of hepatocellular carcinoma.49 Similarly, 
the importance of changes in lipids for the discrimination of 
the grades of astrocytoma21 evidently showed that DESI MS 
can be applied in cancer diagnosis. The tear fluids studied 
earlier had cholesterol, triglycerides, sphingomyelins, PCs, 
and PEs.50 Probably in future, the lipid level changes in the 
tear fluids could also be analyzed for studying the disease 
state or therapeutic progression.
To conclude, our data reports for the first time NCL overex-
pression in RB. The NCL-APT binds preferentially to RB cells 
and inhibits cell proliferation. NCL-APT treatment leads to 
changes in mRNA, miRNA and lipid levels resulting in effec-
tive tumor growth inhibition in vivo. The NCL-APT treatment 
reduced the serum onco-miRNAs. Our data also substan-
tiates the use of intraperitoneal mode of delivery and LNA 
modification for the therapeutic efficacy of NCL-APT. The 
data confirm the effectiveness of DESI MS based lipid profil-
ing for the monitoring of lipid level changes during treatment. 
Thus, further studies using orthotopic or intraocular mod-
els of RB warrant the use of aptamer in RB therapy. Future 
research on tear lipidome of RB using DESI MS could regard 
as a non-invasive method for studying the treatment medi-
ated effects.
Materials and methods
Cell lines and RB sample collection. Y79 and WERI-Rb1 
(Riken cell bank, Japan) were cultured in RPMI 1640 medium 
and MIO-M1 (kind gift from Dr. G. A. Limb) in Dulbecco's 
modification of Eagle's medium (DMEM), respectively at 
37 °C in a 5% CO2 humidified incubator. RB tumor samples 
were collected from the freshly enucleated eyeballs, surgi-
cally removed as a part of the treatment regimen with written 
consent from parents/guardian. Normal retina samples were 
collected from the healthy cadaveric eyes, post corneal trans-
plantation supplied by C U Shah Eye Bank, Medical Research 
Foundation, Sankara Nethralaya. This study was conducted 
at Vision Research Foundation, Sankara Nethralaya, India, 
and was approved by the Vision Research Foundation Insti-
tutional Ethics Board (Ethical clearance no: 249B-2011-P). 
Figure 7 Changes in PC levels upon in vivo assessment of NCL-APT and LNA-NCL-APT. (a) DESI MS images of cryosection from the 
vehicle control and treatment groups. Images represent the distribution of phosphatidylcholines across the tissue sections. (b) H&E stained 
images of the tissue sections. Images were presented without alteration, acquired at 10X magnification.
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RB cells were collected in Rosewell Park Memorial Institute 
(RPMI) media containing 10% FBS, placed on 6-well plate, 
minced well, passed through 23 gauge needle and the sus-
pended cells were washed and used for assays.
Expression of NCL in cell lines, tumors and NCL-APT uptake. 
The NCL expression was studied by quantitative polymerase 
chain reaction (qPCR), flow cytometry, IHC and western blot-
ting on the RB tissues and normal retina. qPCR analysis was 
performed using SYBR green-based method. We performed 
flow cytometry to study the expression of surface NCL, on 
unfixed RB cell lines as well on RB tumor cells obtained from 
enucleated eyes. IHC was performed on deparaffinized tis-
sue sections, post-antigen retrieval. Western blotting was 
performed on cytoplasmic lysate for NCL and β-actin. The 
aptamer binding and uptake was performed on live, fresh, 
unfixed or nonpermeabilized cells and analysed by flow 
cytometry.
NCL-APT treatment—miRNA microarray and miRNA regula-
tions. The effect of NCL-APT on Y79, WERI-Rb1 and MIO-M1 
cell lines were studied by treating cells with various concen-
trations of NCL-APT and LNA-NCL-APT (0.5 to 20 µmol/l) 
and scrambled aptamer (5 and 20 µmol/l) using MTT assay. 
The effective dose or a concentration with lesser cytotoxicity 
was chosen for further studies. miRNA microarrays were per-
formed in duplicates for WERI-Rb1 untreated and NCL-APT-
treated cells. Validation of the miRNAs was performed using 
RNU6B as normalizing control for small RNA. The aptamer-
treated cells were compared to untreated cells and normal-
ized to it. Similarly, the vehicle control samples were used 
for normalizing the changes observed in the aptamer treated 
tissue samples.
In vivo experiments: protein array and integrome analy-
sis. Animal study was performed commercially utilizing 
the facility of Syngene International (Bangalore, India) and 
experimentations were approved by the Institutional Animal 
Ethics Committee (IAEC Protocol Approval No: SYNGENE/
IAEC/430/10–2013). Following aseptic procedure, Y79 cells, 
1 × 107 in 200 µl of serum free media containing 50% of Matri-
gel was injected subcutaneously in the back of 5-week-old 
female nude mice (Hsd: Athymic Nude-Foxn1nu/Foxn1nu). 
Once the tumor was palpable, the animals were random-
ized into four groups (n = 6) and treated with aptamers either 
s.c. or i.p. with 12.5 nmol/dosing for 21 days. Tumor volume 
and body weight were measured every 3 days. The excised 
treated tumor tissues were subjected for mRNA, miRNA, pro-
tein arrays. For the integrome analysis, commonly enriched 
biological categories were taken along with their statistical 
significance and differentially expressed genes and miRNA 
involved for downstream integrome network analysis using 
BridgeIsland Software (Bionivid Technology Pvt Ltd, Banga-
lore, India) and CytoScape V 2.8 to understand treatment 
specific differential regulome.
DESI MS of cell lines and xenograft tumor tissues treated with 
NCL-APT and LNA-NCL-APT. The effect of NCL silencing/
knockdown (siNCL) and NCL-APT on the alteration in lipid 
profile was studied using DESI MS. A 2D DESI ion source 
from Prosolia (Indianapolis, IN) was coupled with Thermo 
Scientific LTQ XL ion trap mass spectrometer (Thermo Sci-
entific, San Jose, CA). The treated cells (5 × 105 cells) were 
washed with PBS and resuspended uniformly to 15 µl 1× 
PBS, spotted on Whatman 42 filter paper and left for drying 
in laboratory condition for 5 minutes. The samples were ana-
lyzed from the filter paper by DESI MS in positive ion mode 
using HPLC grade methanol from Sigma-Aldrich (Bangalore, 
India) as solvent and conditions published earlier.23 The snap 
frozen tumor tissues were sectioned using a Leica cryostat 
and thaw mounted on glass slides and analyzed by DESI MS 
using the same conditions used for the cell lines. In brief, the 
following parameters were maintained throughout the DESI 
MS experiments; spray voltage: 5 kV, solvent flow rate: 5 µl/
minute, nebulizer gas pressure: 150 psi, spray angle: 60° to 
the surface, surface to spray tip distance: 2 mm, atmospheric 
inlet of the mass spectrometer to spray tip distance: 3 mm. 
During imaging by DESI MS, a pixel size of 250 × 250 µm 
was chosen for both the cell lines and tissues. For MS/MS 
experiments, collision induced dissociation (CID) was used.
Statistical analysis. The in vitro results are represented as 
mean ± SD (n ≥ 3), while the in vivo results are represented 
as mean ± standard error of the mean (n = 6). Significance 
was calculated using student’s t-test (paired, two-tailed) 
and the P values were indicated with * for P < 0.05 and ** for 
P < 0.001.
For detailed methods, kindly refer to Supplementary 
Section.
Supplementary material
Table S1. List of masses of the phosphatidylcholines pre-
dicted by MS/MS and database search.
Figure S1. NCL expression, NCL-APT uptake and cellular 
effects on RB cell lines.
Figure S2. miRNA expression and effect of NCL-APT on the 
morphology of RB cell lines.
Figure S3. Stability and effect of NCL-APT and LNA-NCL-
APT in cell lines.
Figure S4. Schematic showing gene regulatory network 
upon NCL-APT treatment in RB.
Figure S5. Effect of NCL-APT treatment and siRNA against 
NCL on lipids by DESI MS.
Figure S6. Effect of NCL-APT treatment on lipids by DESI MS.
Supplementary Section.
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